WitrynaGlobeNewswire +9.25%. Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. Witryna9 mar 2024 · IMRN - Immuron Ltd ADR Stock Price Quote - NASDAQ Morningstar Immuron Ltd ADR IMRN Stock Quote Morningstar Rating Rating as of Mar 9, 2024 …

Immuron Limited Stock Price Today, IMRN Stock Price Chart

Witryna12 kwi 2024 · Immuron Limited (IMRN) Stock Price, Quote & News - Stock Analysis Immuron Limited ( IMRN) Add to Watchlist 1.95 +0.04 (1.96%) At close: Mar 22, … Witryna11 kwi 2024 · MELBOURNE, Australia, April 11, 2024 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to … diane manhoff

Immuron Limited (IMRN) Stock Price, News, Quote & History

Witryna$IMRN Immuron stock rockets after funding by U.S. DoD of new research agreement Shares of Immuron Ltd. IMRN, +46.18% rocketed 49.6% in active premarket trading … Witryna12 kwi 2024 · IMRN has $15.14M in cash and short term investments. This is sufficient to cover its annual cash burn of $2.16M. There are more short-term assets than long-term liabilities on the IMRN balance sheet. Failed Health Checks: IMRN profit margin has gone up by 53.79 percentage points in the past year, but the company is still unprofitable. c# iterate directory